RxDoctor Payments DataLook up a doctor →

Craig Dietz

Internal Medicine · Kansas City, MONPI 1740247097

Payments from drug & device makers

$4,036,766in general payments, 2019–2025

Across 692 payments — averaging $5833.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$3.3M
  • Gilead$449K
  • AbbVie$159K
  • Viiv Healthcare Company$115K
  • Janssen Research & Development, LLC$29K
  • Janssen Products, LP$3K
  • plus $2K from 6 others
$2,900in research payments, 2019–2025

Across 16 payments — averaging $181.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$1K
  • Gilead$1K

What the payments were for

  • Consulting fees$25,36011%
  • Speaking & faculty fees$176,22178%
  • Travel & lodging$17,6588%
  • Food & beverage$6,7773%
  • Education$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,036,766 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala307$1,268,262
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf42$210,768
OdefseyEmtricitab/Rilpiviri/Tenof Ala42$157,146
DovatoDolutegravir Sodium/Lamivudine37$121,073
JulucaDolutegravir/Rilpivirine32$113,569
TivicayDolutegravir Sodium31$68,662
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$48,540
DescovyEmtricitabine/Tenofov Alafenam15$35,206
JardianceEmpagliflozin38$33,463
TrulicityDulaglutide18$26,575
JanuviaSitagliptin Phosphate17$12,557
OzempicSemaglutide11$12,429
FarxigaDapagliflozin Propanediol16$11,026
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$3,774
JanumetSitagliptin Phos/Metformin Hcl12$3,702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$449,363$1,352,007334 claims
Viiv Healthcare CompanyDovato, Juluca, Tivicay$115,052$303,303100 claims
Janssen Products, LPSymtuza$3,500$210,76842 claims
MerckJanuvia, Janumet$3,278,553$16,25929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →